CGEM vs CLYM: fair value comparison
Cullinan Therapeutics, Inc. and Climb Bio, Inc. · Updated 2026-10-19
CGEM has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. CLYM has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, CGEM currently ranks higher by quality score.
| CGEM | CLYM | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $12.93 | $9.82 |
| 12-month range | $7.19–$22.95 | $1.64–$17.84 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #228 of 301 Healthcare | #229 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| RSI zone | Oversold | Oversold |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The lower-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: CGEM fair value analysis · CLYM fair value analysis